- Clinical Trials
- April 2025
- 40 Pages
Global
From €897EUR$1,000USD£788GBP
€1122EUR$1,250USD£984GBP
- Report
- May 2025
- 150 Pages
Global
From €2287EUR$2,549USD£2,008GBP
€2691EUR$2,999USD£2,362GBP
- Report
- August 2023
- 150 Pages
Global
From €5339EUR$5,950USD£4,686GBP
- Report
- June 2024
- 200 Pages
Global
From €5707EUR$6,360USD£5,009GBP
€7134EUR$7,950USD£6,261GBP
- Report
- July 2024
- 133 Pages
Global
From €2243EUR$2,500USD£1,969GBP
Cataplexy drugs are a type of central nervous system (CNS) drug used to treat cataplexy, a sudden loss of muscle tone caused by strong emotions. These drugs are typically prescribed to people with narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden, uncontrollable episodes of sleep. Cataplexy drugs work by increasing the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which help regulate mood and alertness. Commonly prescribed cataplexy drugs include modafinil, sodium oxybate, and venlafaxine.
Some of the major companies in the cataplexy drug market include Cephalon, Inc., Jazz Pharmaceuticals, Inc., Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. Show Less Read more